Business Context and Reporting Period
This Form 8-K Current Report, filed on August 31, 2020, by Galectin Therapeutics Inc. (Nasdaq: GALT), details significant changes in corporate leadership and board composition. The report covers events effective as of August 31, 2020, and September 2, 2020.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and board appointments.
Material Changes
Executive Leadership Transition
- Appointment of CEO: Joel Lewis was appointed Chief Executive Officer, effective September 2, 2020. He succeeds Dr. Harold Shlevin, who is retiring.
- CEO Compensation: Mr. Lewis receives an annual base salary of $500,000. Payment structure is 20% cash and 80% in Deferred Stock Units (DSUs). He is eligible for a performance bonus up to 50% of base salary (also split 20% cash/80% DSU). He received an initial grant of options to purchase 250,000 shares, vesting quarterly over 12 quarters.
- Retirement of Former CEO: Dr. Shlevin receives a 2020 cash bonus of $210,000 in lieu of other bonuses. He will transition to a consulting role at $432 per hour (minimum $8,640 per month) for an initial one-year term. His existing stock options will continue to vest during the consulting period.
Board of Directors Expansion
- The Board size increased from nine to eleven members.
- New Appointments: Elissa J. Schwartz and Richard A. Zordani were appointed to fill the new directorships.
- Committee Roles: Mr. Zordani will serve as Chair of the Audit Committee and financial expert. Mr. Lewis, previously Audit Committee Chair, will remain on the Board.
- Director Compensation: Non-employee directors receive an annual cash retainer of $35,000. The Audit Committee Chair receives an additional $15,000 annual retainer. New directors receive prorated compensation for 2020.
- Verify the vesting schedule and exercise price of the 250,000 stock options granted to Joel Lewis.
- Confirm the total cash outflow impact of the $210,000 bonus to Dr. Shlevin and the new CEO's cash salary component.
- Review the attached Employment Agreement (Exhibit 10.1) and Retirement Agreement (Exhibit 10.3) for detailed definitions of "Cause" and "Good Reason."
- Assess the strategic fit of the new directors' backgrounds (financial restructuring vs. disease modeling) relative to the company's current pipeline.
Outlook, Risks, and Contingencies
The filing outlines specific termination provisions for the new CEO, including a lump-sum cash payment upon termination without "Cause" or resignation for "Good Reason." The filing notes that Dr. Shlevin remains eligible for a "pharma deal achievement bonus" if a qualifying transaction occurs during his consulting term. No specific financial risks or market outlooks are provided in this document.